ImmunityBio, Inc. (IBRX)

NASDAQ • Healthcare

$10.29

+$1 (+10.9%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$9.39

Day Range$9.39 - $10.55

Avg. Volume (3M)13.4M

Market Cap$10.7B

52 Week Range

$1.95$12.43

Next EarningsIn 30 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$51.2M100%

Gross Profitminus cost of goods$50.9M99%

Fundamentals & Financials

Revenue (TTM)

$165.7M

Net Income (TTM)

-$992.3M

EPS (TTM)

-$0.97

ROA (TTM)

-157.89%

Current Ratio

5.72

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$0.1

+30.0%Q4 2025-$0.07

+25.0%Q1 2026-$0.06

-675.0%Q2 2026-$0.62

-175.0%Q3 2026-$0.22

Nov 3

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About ImmunityBio, Inc.

ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company that develops therapies and vaccines for cancer and infectious disease using immunotherapy and cell therapy platforms. In FY2025, it generated $113.3 million in revenue. Its programs span antibody-cytokine fusion proteins, immunomodulators, vaccine technologies, NK cell therapies, and T-cell strategies.

Name

ImmunityBio, Inc.

CEO

Richard Gerald Adcock

Website

immunitybio.com

Industry

Healthcare

Year Founded

2014

Employees

688

Today's Snapshot

AI-generated

The day ended with IBRX 10.8% higher at 10.29, while its sector was flat. Volume was roughly twice its usual level. ImmunityBio was upgraded to Strong Buy by Jefferies, an investment bank.

Trading Volume

Above 10d avg 15.1M

30.7M

vs S&P 500 Today

Strong Outperformance

+10.05%

Updated: October 2, 2026 at 20:03 UTC

Technical Indicators

6 Buy1 Neutral1 Sell

ImmunityBio shows a strong bullish technical setup with price well above short-, medium- and long-term moving averages and a large, positive on-balance volume that underpins the advance. Trend strength is robust by ADX, and momentum is decisively positive with a very high CCI and a positive MACD, although RSI is at overbought territory suggesting short-term caution. ATR reflects elevated volatility, but the classic pivot lies below the market, reinforcing support for the current uptrend. Technical takeaway: strong buy bias as price and volume confirm a powerful trend despite elevated volatility.

All signals